Early Market Access for Pharmaceuticals in EU: What Is the Impact of Ema’s Accelerated Assessment Procedure?

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.09.710
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Principle of Transparency and Access to Documents in the EU: For What, for Whom and of What?

SSRN Electronic Journal
2020English

Php316 - Exploring Biosimilar Market Access Considerations Across the Eu

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Dilemmas in Regulation of the Market for Pharmaceuticals

Health Affairs
MedicineHealth Policy
2003English

Drug Repurposing in Pharmaceutical Industry and Its Impact on Market Access: Market Access Implications

Journal of Market Access & Health Policy
2014English

Pnd110 - Gene Therapy Products – Market Access Situation in Eu and in Slovakia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Accepted for the Impact Factor – What Is the Impact of Eurosurveillance?

Eurosurveillance
EnvironmentalVirologyPublic HealthEpidemiologyMedicineOccupational Health
2009English

Where Is Scientific Evidence Supporting EU Policy on BSE and Pharmaceuticals?

BMJ
1998English

What Is New in the EU Strategy in the Western Balkans?

Sovremennaya Evropa
EconomicsInternational RelationsEconometricsPolitical Science
2018English

Php319 - Mandatory Joint Clinical Assessment – What Is the Additional Insight From Eu-Nethta vs. Ema?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy